newsfilter
← Latest News
ACCESS Newswire·

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has